Drug Profile
Ciclosporin/Omeprazole - Perle Bioscience
Alternative Names: Omeprazole/ciclosporin - Perle Biosciences; PRL-001Latest Information Update: 28 Oct 2018
Price :
$50
*
At a glance
- Originator Perle Bioscience
- Class 2 pyridinylmethylsulfinylbenzimidazoles; Antihyperglycaemics; Ciclosporins; Gastric antisecretories; Small molecules
- Mechanism of Action Calcineurin inhibitors; Free radical inhibitors; Immunosuppressants; Mitochondrial permeability transition pore inhibitors; P-glycoprotein inhibitors; Proton pump inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Type 1 diabetes mellitus
Most Recent Events
- 28 Oct 2018 No recent reports of development identified for clinical-Phase-Unknown development in Type-1 diabetes mellitus in Spain (PO)
- 28 Oct 2016 Clinical development is ongoing in Spain (Perle Bioscience pipeline; October 2016)
- 15 Apr 2016 Perle Bioscience withdraws a clinical trial for Type-1 diabetes mellitus in Spain (EudraCT 2015-000105-39)